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Objective. Our objective was to assess the ability of real-time PCR to predict in vitro resistance in isolates of group B streptococcus
(GBS). Methods. The ﬁrst real-time PCR assays for the genes known to confer resistance to erythromycin and clindamycin in GBS
were developed. Three hundred and forty clinical GBS isolates were assessed with these assays and compared with conventional
disk diﬀusion. Results. The presence of an erythromycin ribosome methylation gene (ermBo rermTR variant A) predicted in vitro
constitutive or inducible resistance to clindamycin with a sensitivity of 93% (95% CI 86%–97%), speciﬁcity of 90% (95% CI 85%–
93%),positivepredictive value of76% (95% CI67%–84%), andnegative predictive valueof 97% (95%CI94%–99%).Conclusion.
This rapid and simple assay can predict in vitro susceptibility to clindamycin within two hours of isolation as opposed to 18–24
hours via disk diﬀusion. The assay might also be used to screen large numbers of batched isolates to establish the prevalence of
resistance in a given area.
Copyright © 2007 Wilfred P. Dela Cruz et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Each year in the US 8000 neonatal cases of sepsis due to GBS
are reported [1]. Up to 30% of women carry GBS in the uro-
genital tract, intestinal tract, or both. Intrapartum antibiotic
chemoprophylaxis remains the key to preventing neonatal
disease. Penicillin is the drug of choice for prophylaxis and
treatment of GBS infection. In patients allergic to penicillin,
erythromycin and clindamycin are the commonly used al-
ternatives. The proportions of GBS isolates with in vitro re-
sistance to erythromycin and clindamycin have steadily in-
creased since 1996 [2]. The prevalence of resistance among
invasive GBS isolates in the United States and Canada ranged
from 7% to 25% for erythromycin and from 3% to 15% for
clindamycin in reports published between 1998 and 2001.
The genetic basis for macrolide and lincosamide resis-
tance in GBS has been studied extensively [3]. The ermTR
variantA(ermTR)andermBgenesmodifyasitein23SrRNA
common to the binding of macrolides, lincosamides, and
streptogramin B antibiotics. The macrolide eﬄux (mefA)
gene allows the bacterium to actively expel the antibiotic
from the interior of the cell [4]. Both the ermTR and
ermB genes have been associated with the MLSB constitutive
phenotype in GBS (erythromycin-resistant, clindamycin-
resistant); the ermTR gene with the MLSB inducible phe-
notype(erythromycin-resistant,clindamycin-susceptible,D-
test positive); and the mefA gene with the M pheno-
type (erythromycin-resistant, clindamycin-susceptible, D-
test negative) [5].
Current recommendations state that all pregnant women
should be screened at 35–37-week gestation for vaginal
and rectal GBS colonization, and that susceptibility testing
should be performed on isolates from women with penicillin
allergy [2]. The CDC further recommends D-testing for GBS
isolates that are erythromycin-resistant and clindamycin-
susceptible on initial disk diﬀusion testing [6]. Vancomycin
is now the recommended antimicrobial prophylaxis for peri-
natal GBS disease prevention in the penicillin allergic patient
whose isolate is known to be resistant to erythromycin and
clindamycin (constitutively or inducibly), or whose isolate
has not been tested for resistance. This policy is at odds with
Hospital Infection Control Practices Advisory Committee2 Infectious Diseases in Obstetrics and Gynecology
(HICPAC) guidelines urging limitation of vancomycin use
[7].
While a newly licensed PCR-based diagnostic test [8]
allows for intrapartum detection of GBS colonization in
women who have had no prenatal care or for whom cul-
ture results are otherwise unknown, vancomycin would still
be indicated in the penicillin allergic patient with a positive
test result due to a lack of susceptibility information. The
disk diﬀusion method, which takes 18–24 hours to be per-
formed, is currently the most commonly used method for
determining GBS susceptibilities. An assay for the rapid de-
tection of the erm and mefAg e n e sm i g h ta l l o wf o rm o r e
judicious use of vancomycin. The aim of the present study
was to develop rapid assays using real-time PCR for detec-
tion of these genes and to assess their performance using
the disk diﬀusion method as the standard. A secondary goal
was to assess the susceptibility of isolates demonstrating con-
stitutive clindamycin resistance to a new ketolide antibiotic,
telithromycin.
2. METHODS
Three hundred and forty consecutive, unique patient GBS
isolates from screening cultures collected at our facility in
2004 were studied. Disk diﬀusion testing of the isolates was
accomplished according to National Committee for Clinical
Laboratory Standards (NCCLS) guidelines [9]. Brieﬂy, GBS
growth from an overnight (18-hour) sheep blood agar plate
was suspended in 0.9% saline to a density equivalent to the
turbidity of the 0.5 McFarland standards. This suspension
was inoculated on Mueller-Hinton agar supplemented with
5% deﬁbrinated sheep blood. Erythromycin (15µg, Remel,
Lenexa,Kan,USA)andclindamycin(2µg,Remel)diskswere
placed on the plates. The plates were incubated at 35◦Ci na n
atmosphere of 5% CO2 f o r2 0t o2 4h o u r sb e f o r em e a s u r i n g
zones of inhibition.
D-testing was performed for erythromycin-resistant/
clindamycin-susceptible isolates, as described previously
[10]. Clindamycin disks and erythromycin disks were placed
approximately 15mm apart on Mueller-Hinton agar supple-
mented with 5% deﬁbrinated sheep blood that had been in-
oculated with a standardized (0.5 McFarland) suspension of
GBS. The plates were incubated at 35◦Ci na na t m o s p h e r eo f
5% CO2 for 20 to 24 hours before observing for D-shaped
blunting of the circular zone of inhibition around the clin-
damycin disks on the side facing the erythromycin disk. Fur-
ther susceptibility testing was performed for 50 isolates ex-
hibitinganMLSB constitutivephenotypeusingtelithromycin
(15µg, Sanoﬁ-Aventis, Bridgewater, NJ, USA) disks.
Genomic DNA fromGBS isolates was extractedusing the
MagNA Pure LC automated extraction system (Roche Ap-
plied Science, Indianapolis, Ind, USA) per manufacturer’s
recommendation.Real-timeﬂuorescentPCRwasusedtode-
tect cfb, a GBS-speciﬁc gene target, and the MLS resistance
genes (ermTR, ermBa n dmefA). Discordant results were
retested for conﬁrmation.
The primers and hybridization ﬂuorescent resonance en-
ergy transfer (FRET) probes were designed using the Light-
Cycler probe design software version 1.0 (Roche Applied
Science, Indianapolis, Ind, USA). The primers for the
247 bp fragment of cfb gene (GenBank accession no.
NC 004116) are as follows: forward primer (33–48) 5  to 3 ,
AACTCTAGTGGCTGGT; and reverse primer (279–264) an-
tisense 5  to 3 , GGCACGCAATGAAGTC. The internal
FRET hybridization probes for cfb gene fragment have the
following sequence: upstream probe (93–112) 5  to 3 ,
AGTGACAACTCCACAAGTGG-FITC; downstream probe
(115–144) 5  to 3 , 640RED-AATCATGTAAACAGTAA-
TAATCAAGCCCAG-PHOSPHATE. The primers for the
162 bp fragment of ermB (GenBank accession no. X72021)
are as follows: forward primer (390–406) 5  to 3 ,C T A -
CAAGCGTACCTTGG; and reverse primer (551–533) an-
tisense 5  to 3 , TCTGGAACATCTGTGGTAT. The inter-
nal FRET hybridization probes for 162 bp ermBg e n ef r a g -
ment have the following sequence: upstream probe (468–
483) 5  to 3 , GCTGCCAGCGGAATGC-FITC; downstream
probe (486–5143) 5  to 3 , 640RED-TCATCCTAAAC-
CAAAAGTAAACAGTGTCT-PHOSPHATE. The primers
for the 281 bp fragment of ermTR gene (GenBank acces-
sion no. AF443782) are as follows: forward primer (505–
524) 5  to 3 , CCTTATTGTAGAGAGGGGAT; and reverse
primer (785–768) antisense 5  to 3 , GCTTCAGCACCT-
GTCTTA. The internal FRET hybridization probes for
ermTR gene detection are the following: upstream probe
(607–627) 5  to 3 , GCCACGAGCATATTTTCACCC-FITC;
downstream probe (630–660) 5  to 3 : 640RED-AGCC-
TAATGTAGATTCTGTATTGATTGTACT-PHOSPHATE-
. The primers for the 179 bp fragment of mefAg e n e
(GenBank accession no. AY071836) are as follows: forward
primer (294–309) 5  to 3 , GGAGCTACCTGTCTGG; and
reverse primer (472–457) antisense 5  to 3 , CAACTGC-
CGGACTAAC. The internal FRET hybridization probes for
mefA gene detection are the following: upstream probe
(341–364) 5  to 3 , TTGGAACAGCTTTTCATACCCCAG-
FITC; downstream probe (367–388) 5  to 3 , 640RED-
CTCAATGCGGTTACACCACTTT-PHOSPHATE. The real-
time ﬂuorescent PCR cycling was carried out in the Light-
Cycler (Roche Applied Science, Indianapolis, Ind, USA) in
20µL reaction mixture containing 5µL( ∼1ng) template,
5mMMgCl 2, 0.2mM dNTP, 1 U Taq polymerase, 500nM
forward and reverse primers, and 100nM upstream and
downstream hybridization probes. Cycling conditions in-
clude an initial denaturation step at 94◦C for 60 seconds,
followed by 35 cycles which consist of annealing at 60◦C
f o r3 0s e c o n d s ,e x t e n s i o na t7 2 ◦C for 5 seconds, and de-
naturation at 94◦C for 1 second. Progress of real-time ﬂu-
orescent PCR was monitored in channel 2 on the LightCy-
cler. During the optimization phase of the real-time PCR as-
says, the production of a single PCR product was conﬁrmed
in 3% agarose gel electrophoresis visualized by SYBR Green
(Molecular Probes, Eugene, Ore, USA) staining at 1:10 000
dilution.
STATA version 9.0 (College Station, Tex, USA) was used
to calculate sensitivity, speciﬁcity, positive predictive value,
and negative predictive value, and their corresponding 95%
conﬁdence intervals.Wilfred P. Dela Cruz et al. 3
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Figure 1: The intensity of the ﬂuorescence signal (F2) versus cy-
cle number plot. A 162 bp fragment of ermB gene was ampliﬁed
from genomic DNA of E. faecium (asterisk), ermB-positive GBS
isolate (closed triangle), and GBS isolated from patient number
6 (closed square). No ﬂuorescence ampliﬁcation was observed in
ermB-negative GBS (ATCC 12386) (open triangle) and negative
control (water, open square), or the rest of patient isolates tested.
3. RESULTS
The PCR assays were optimized in the LightCycler instru-
ment. Figures 1 and 2 demonstrate representative ﬂuores-
cence curves and agarose gel electrophoresis results for the
ermB assay. Each component assay was run in separate tubes
with the same PCR reaction and cycling conditions.
A total of 340 unique clinical GBS isolates collected from
vaginal-rectal swabs were analyzed in this study. All isolates
were positive for GBS-speciﬁc cfb gene by real-time PCR.
One hundred isolates (29%) demonstrated resistance to ery-
thromycin and/or clindamycin via disk diﬀusion testing
(Table 1). Among the 100 resistant isolates, 79 demonstrated
an MLSB constitutive phenotype, 8 an MLSB inducible phe-
notype, and 11 an M phenotype, while 2 were susceptible to
erythromycin, but were resistant to clindamycin. No resis-
tance to telithromycin was detected among the 50 randomly
selected MLSB constitutive strains that were tested.
Among the 340 isolates, a single resistance gene was de-
tected in 105 isolates (31%), while 21 isolates (6%) harbored
two genes. The genotype and phenotype were discordant in
14% of isolates (Table 2). Among the 240 fully susceptible
isolates, 33 (14%) contained at least one resistance gene. At
least one resistance gene was detected in 93 of the 100 re-
sistant isolates. Presence of the mefA gene predicted the M
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Figure 2: Agarose gel electrophoresis. PCR ampliﬁcation products
in E. faecium, ermB-positive GBS, and isolate from patient number
6wereconﬁrmedwith3%agarosegelelectrophoresis.Lanes1-2are
PCR H2O, Lanes18-19 are patient number 6, Lane 26 is E. faecium,
and Lane 27 is ermB-positive GBS control.
phenotype with a sensitivity of 55% (95% CI 23%–83%),
speciﬁcity of 94% (95% CI 90%–96%), PPV of 22% (95% CI
9%–42%),andNPVof98%(95%CI96%–99%).Presenceof
at least one erm gene within an isolate predicted constitutive
or inducible resistance to clindamycin with a sensitivity of
93% (95% CI 86%–97%), speciﬁcity of 90% (95% CI 85%–
93%), positive predictive value of 76% (95% CI 67%–84%),
and negative predictive value of 97% (95% CI 94%–99%).
Because we had no a priori estimates for negative predic-
tive value, post hoc power analyses were conducted using the
obtained NPV of 97% to assess whether the sample size col-
lected was suﬃcient to exclude negative predictive values as
low as 90% for erm gene predicting clindamycin resistance.
I no r d e rt ob e9 5 %c e r t a i n( p o w e r= 0.95) that a negative
predictive value as low as 90% was excluded (alpha level,
two-tailed = 0.05), at least 133 test negative patients would
be necessary [11]. Our number of test negative patients ex-
ceeded this value, making the power more than adequate for
our research question.
4. DISCUSSION
We developed a real-time PCR method that can be used to
rapidly detect macrolide resistance genes (ermB, ermTR, and4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Detection of macrolide and lincosamide resistance genes in GBS. E denotes erythromycin; CC denotes clindamycin; S denotes
susceptible; R denotes resistant.
Phenotype Number of
isolates
ermB
only
ermTR
only
mefA
only
ermBa n d
ermTR
ermBa n d
mefA
ermTR
and mefA
No erm
or
mefA
E-S, CC-S 240 9 9 13 — 2 — 207
E-R, constitutive CC-R 79 51 7 — 10 5 1 5
E-R, CC-S —— — — — — ——
D-test + (inducible CC-R) 8— 7 — 1 — — —
D-test - (M phenotype) 11 3 1 4 — 2 — 1
E-S, constitutive CC-R 2— 1 — — — —1
Total 340 63 25 17 11 9 1 214
Table 2: Comparison of discordant phenotype and genotype among 340 GBS isolates. E denotes erythromycin; CC denotes clindamycin; S
denotes susceptible; R denotes resistant.
Phenotype Genotype No. of isolates
E-S, CC-S ermBo n l y 9
E-S, CC-S ermTR only 9
E-S, CC-S mefA only 13
E-S, CC-S ermBa n dmefA2
E-R, CC-S, D-test - (M phenotype) ermBo n l y 3
E-R, CC-S, D-test - (M phenotype) ermTR only 1
E-R, CC-S, D-test - (M phenotype) ermBa n dmefA2
E-R, constitutive CC-R No mechanism detected 5
E-S, constitutive CC-R ermTR 1
E-S, constitutive CC-R No mechanism detected 1
Total — 46 (14%)
mefA) from a pure GBS isolate. Previous studies have fo-
cused on identifying genes present in resistant isolates of
GBS. To make these molecular techniques useful to clini-
cians,onemustaskthequestioninreverse:does thepresence
of one of these genes predict in vitro resistance and possi-
ble treatment failures? The critical issue is the disparity be-
tween genotype and phenotype. A previous study examined
this relationship in 1043 strains of macrolide-resistant Strep-
tococcus pyogenes and Streptococcus pneumoniae and found a
10.2% rate of error when predicting the genotype from phe-
notypic data [12]. While we observed a slightly higher level
of discordance between genotype and phenotype in GBS
(14%), our data suggest that the absence of detection of an
erm gene predicts in vitro susceptibility to clindamycin with
an NPV suﬃcient to make the assay clinically useful.
While this would cut the 18–24 hours that it takes to
perform disk diﬀusion testing down to 1-2 hours, the ideal
molecular test would be performed directly from a clinical
specimen.Becausemanyotherbacteriathatcolonizetheuro-
genital and intestinal tracts harbor erm genes, direct analysis
of clinical specimens with these assays would likely not yield
useful results. Moreover, erm genes are located in a conjuga-
tive S. agalactiae plasmid, pIP501, which is highly homolo-
gous to numerous plasmids found in other bacterial species
[13]. Thus, detection of clindamycin resistance in GBS di-
rectly from a clinical specimen, as does a commercially avail-
able PCR-based test for detecting MRSA [14], may not be
possible without prior isolation.
An estimated 3%–10% of the general population is aller-
gic to penicillin [15]. It would be ideal if an alternate agent
with 100% eﬃcacy and with no propensity for inducing re-
sistance was available. Telithromycin, the ﬁrst ketolide to re-
ceive FDA approval in the US, may be such an agent. Our
ﬁndings mirror those of other researchers: telithromycin is
broadly active against GBS, including those strains exhibit-
ing resistance to erythromycin and clindamycin [16, 17]. A
recent report describing 51 telithromycin-susceptible strains
of MLSB constitutive GBS that showed inducible resistance
to telithromycin in the presence of erythromycin does, how-
ever, raise the possibility that resistance might develop while
a patient is on therapy and result in a treatment failure [18–
20]. Still, given its excellent in vitro activity against this or-
ganism, the short course of therapy used for this indication,
andthelackofconvincingevidenceregardingtheclinicalim-
portance of this type of inducible resistance, clinical testing
of telithromycin as intrapartum chemoprophylaxis against
neonatal GBS infection seem warranted.
We observed two isolates that were erythromycin-
susceptible and clindamycin-resistant. While altered expres-
sion or regulation of the ermTR gene present in one of these
isolates might explain its phenotype, the other strain did not
contain an erm or mefA gene. This phenotype, the geneticWilfred P. Dela Cruz et al. 5
basis for which remains unknown, is rare in North America,
butis already widespreadin New Zealand[21]. Theexistence
of such strains presents a pitfall in inferring clindamycin sus-
ceptibility from erythromycin susceptibility when only the
latter is tested. This underscores the importance of perform-
ing in vitro testing for resistance to clindamycin on isolates
obtained from persons with penicillin allergy.
Finally, we observed 5 isolates that were resistant to both
erythromycin and clindamycin, and yet contained none of
the common resistance genes for which we tested, which is
consistent with previous reports [22, 23]. This may suggest
analternatemechanismofresistance.Aplausiblemechanism
is mutation in the 23S rRNA. Such mutations have been re-
ported to cause macrolide resistance in S. pneumoniae [24].
Further study of these isolates is warranted.
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